MedWatch

Zealand will go it alone with heart medicine

For the first time ever Zealand Pharma has initiated phase II studies of a candidate drug.

Foto: Zealand Pharma/PR

The candidate drug danegaptid signals a significant milestone for Zealand Pharma, as it becomes the first candidate in phase II studies conducted exclusively by the Danish company.

When Zealand Pharma went public the company’s management announced that they aimed at bringing the candidate drug ZP2929 to phase II by themselves, but the Danes received an offer they could not refuse from Boehringer Ingelheim and signed a partnership deal for the development of the drug, which is still showing great promise in the treatment of diabetes and obesity.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier